Variable | Median (IQR) or N (%) |
N | 483 |
Age (years) | 44.5 (36, 51.9) |
Disease Duration (years) | 8.8 (5.3, 16) |
Neutrophil-lymphocyte ratio | 2.1 (1.54, 2.9) |
Monocyte-lymphocyte ratio | 0.2 (0.15, 0.28) |
Expanded Disability Status Scale | 2 (1, 3) |
Gender | |
• Female | 347 (71.8%) |
• Male | 136 (28.2%) |
Smoking Historya | |
• No | 233 (54.2%) |
• Yes | 197 (45.8%) |
Body mass index (BMI)a | 26.2 (22.8, 31.1) |
Multiple sclerosis disease category | |
• Clinically isolated syndrome | 15 (3.1%) |
• Relapsing-remitting | 370 (76.6%) |
• Secondary progressive | 65 (13.5%) |
• Primary progressive | 33 (6.8%) |
Disease modifying therapy | |
• Untreated | 110 (22.8%) |
• Interferon-β | 216 (44.7%) |
• Cyclophosphamide | 14 (2.9%) |
• Fingolimod | 8 (1.7%) |
• Glatiramer Acetate | 51 (10.6%) |
• Mycophenolate Mofetil | 33 (6.8%) |
• Natalizumab | 37 (7.7%) |
• Other | 14 (2.9%) |
Neuroimaging and patient-reported outcome measures | Median (IQR); N |
Brain parenchymal fraction | 0.85 (0.81, 0.88); 334 |
Cerebral T2-hyperintense lesion volume (mL) | 1.57 (1.27, 2.03); 334 |
Center for Epidemiological Studies Depression Scale | 29 (24, 36); 479 |
Modified Fatigue Inventory Scale | 29 (14, 41); 425 |
Modified Social Support Scale | 85.4 (71.1, 98.4); 477 |
SF-36 Physical composite | 46.6 (37.9, 54.3); 471 |
SF-36 Mental composite | 50.9 (42.5, 56.4); 471 |